Immunovaccine Inc. is a Canada-based clinical stage vaccine and immunotherapy company. The Company discovers and develops activators of the immune system to treat cancer and prevent infectious diseases. The Company�s DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The Company has advanced two T cell activation therapies for cancer through Phase I human clinical trials. The Company has research collaborations with research organizations, including the National Institutes of Health (NIH) in the United States. It has licensed the delivery technology to Zoetis, formerly the animal health division of Pfizer, Inc. for the development of vaccines for livestock.